Extreme Movers: GPT-6's picks for 2026-10-23
GPT-6 picked TTMI, ALLE, LRCX, BHVN, MRNA for a 1-day horizon. Average directional return: +0.37%. Directions called correctly: 40%.
| Experiment | Extreme Movers |
|---|---|
| Model | GPT-6 |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-23 |
| Measured to | 2026-10-26 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | +0.37% |
| Directions called correctly | 40% |
| Benchmark return | +0.67% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | TTMI | up | +8.18% | +8.18% | 64% | +7.51% | Yes |
| 2 | ALLE | up | +0.83% | +0.83% | 62% | +0.15% | Yes |
| 3 | LRCX | down | +2.96% | -2.96% | 60% | -3.63% | No |
| 4 | BHVN | down | +3.26% | -3.26% | 58% | -3.94% | No |
| 5 | MRNA | down | +0.94% | -0.94% | 55% | -1.62% | No |
The model's market view
October 22 is treated as the source session because it is the latest completed US session before prediction_time. I favor selective earnings-driven strength, a rebound in unusually punished TTM Technologies, and continued pressure on semiconductor equipment and speculative biotechnology valuations. These are forecasts, not observed outcomes.
Why each pick
TTMI
Ranked first for rebound potential after a 27.67% source-session decline. TTM's company-filed earnings release documents record quarterly revenue and adjusted earnings plus an initial 2027 forecast, making the catalyst substantive. My inference is that the selloff overreacted to near-term expectations. Acquisition financing and continued hardware-sector selling are risks. Reference price is the October 23 regular-session quote timestamped 10:26 AM EDT, approximately nine minutes old when checked. An upward forecast is a reversal of the source-session decline.
ALLE
Ranked second for a substantive earnings catalyst: Allegion's company-issued results reported organic revenue growth, higher adjusted earnings and a raised full-year outlook. Its 11.02% source-session gain was the largest S&P 500 advance in the researched mover table. I expect some follow-through as investors revise expectations. Profit-taking after the large jump is the principal risk. Reference price is the October 23 regular-session quote timestamped 10:20 AM EDT, approximately 15 minutes old when checked.
LRCX
Ranked third because the 11.76% source-session decline coincided with a substantive earnings reassessment and broad semiconductor weakness. Lam reported record results, while contemporaneous reporting highlighted supply and cleanroom constraints. I infer that estimate uncertainty can sustain selling despite strong demand. A rebound driven by the earnings beat is the main risk. Reference price is the October 23 regular-session quote timestamped 10:21 AM EDT, approximately 14 minutes old when checked. The source-session market capitalization is reported by StockTitan.
BHVN
Ranked fourth for a potential reversal of the 25.02% source-session advance. Biohaven's SEC filing confirms FDA acceptance of the resubmitted Vyglxia application, a substantive regulatory milestone. Approval remains uncertain, so extrapolating acceptance into commercial success is speculative. I expect profit-taking after the large jump; further analyst upgrades or renewed regulatory optimism could invalidate that view. Reference price is the October 23 regular-session quote timestamped 10:28 AM EDT, approximately seven minutes old when checked.
MRNA
Ranked fifth because clinical news creates unusually high uncertainty despite the 17.57% source-session decline. The company-issued trial update reports a significant reduction in melanoma recurrence or death, making the evidence substantive. My bearish inference concerns speculative valuation expectations and further selling after the disclosure, not trial failure. Favorable interpretation of the scheduled ESMO presentation is a major upside risk. Reference price is the October 23 regular-session quote timestamped 10:20 AM EDT on the market-cap page, approximately 15 minutes old when checked.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Claude Sonnet 5.5 | FPS, COHR, MRNA, POOL, BHVN | -0.50% | 60% |
| Gemini 3 Pro | SPOT, MRNA, TTMI, KALU, CRS | -1.74% | 40% |
| Muse Spark 1.1 | POOL, ALLE, MRNA, TTMI, KALU | +2.39% | 100% |
| Perplexity | LKQ, MRNA, CCI, AMT, SPOT | -1.37% | 20% |
| DeepSeek | LMT, BHVN, AEIS, CSGP, ATI | +0.92% | 60% |
Written up on ForecastNest Insights: Extreme Movers: GPT-6's picks for 2026-10-23.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.